Maersk Expands Columbia Sportswear Partnership with UK Warehousing Deal

Nike, Target, Columbia Sportswear, and Amer Sports received tariff refunds, boosting their net income. Nike got $986M, Target $994M, Columbia $78M, and Amer $50.1M. Some firms raised prices, leading to lawsuits from consumers seeking refunds. Companies absorbed some costs, while others passed them to consumers.

Columbia Sportswear reported Q2 net sales of $614.4m, up 2% year on year, with operating income of $30.9m. Gross margin rose to 58.3%, with about 980 bps attributed to US tariff refunds. Net income was $26.6m, or $0.52 diluted EPS. For 2026, it forecasts sales $3.43bn-$3.50bn and EPS $4.45-$4.90, assuming tariff rates stay unchanged.

The Trump administration said U.S. Customs and Border Protection has started barring imports of clothing made by two affiliated Jordan manufacturers, Needle Craft and Casual Wear, after finding evidence of forced labor. The firms supply brands including Columbia and Under Armour, according to supplier lists. CBP issued five and six WROs this fiscal year under Section 307. Jordan’s 2025 exports to the U.S. were about $3.1B, with ~$2B in clothing/textiles.

SFL Corporation ordered two 93,000 cbm ammonia carriers for $216 million, deliverable in 2028. The company also secured long-term charters with an oil major, adding $162 million to its backlog. CEO Ole B. Hjertaker highlighted the investment's accretive nature and the charterer's investment-grade status. The total fixed-rate charter backlog for 2026 exceeds $1.3 billion.

Chevron (CVX) announced senior leadership changes effective January 1, 2027. Mark Nelson will focus on strategy and business development, Eimear Bonner will lead Oil, Products & Gas, Jeff Gustavson will become CFO, and Brent Gros will head New Energies and AI strategy. CEO Mike Wirth praised the new leaders' expertise and commitment.

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.